


Daiichi Sankyo Group Position Statement on Access to Healthcare



Introduction:

The goal of pharmaceutical companies is to act for the benefit of patients and their families by creating pharmaceuticals that address the various medical needs seen around the world.

At the Daiichi Sankyo Group, our Purpose is to contribute to the enrichment of quality of life around the world. Seeking to accomplish this Purpose, we leverage various internal capital such as human capital, intellectual capital, financial capital, and social and relationship capital through partnerships and open innovation to take advantage of our strengths in terms of Science & Technology, Global Organization & Talent, and Long-term Commitment in order to advance its business activities and thereby contribute to the progress of society.

Pharmaceutical companies face various challenges of access to healthcare to be addressed, such as unmet medical needs and access barriers to essential healthcare caused by social factors such as public health, education, and income inequality.

Our position on Access to Healthcare

We work to address access to healthcare across our value chain, which spans everything from research and development to manufacturing, sales & marketing, and quality & safety management, and prioritizes the following three areas: Research and Development, Availability, and Capacity Building.

We have a "Head of Access to Healthcare (Head of Global Corporate Strategy)" to lead efforts to address these issues and improve access to healthcare through collaboration with partners as well as relevant organizations within the Daiichi Sankyo Group.

Through addressing these issues, we contribute to the accomplishment of the Sustainable Development Goals set forth by the United Nations, particularly- Goal 3: "Ensure healthy lives and promote well-being for all at all ages."

Research & Development

We leverage the research and development capabilities that have been honed over our years of operating as a drug discovery-oriented company to continually create innovative pharmaceuticals that improve upon current standard of care disease management and thereby develop a business that helps improve patient health.

To rapidly adopt the countless findings created worldwide and to effectively meet various medical needs, we establish and strengthen partnerships in drug discovery and technology through many approaches for expansion of external networks and

securement of various innovation sources and promotes to integrate a diverse range of perspectives into its drug discovery research efforts.

Through our research and development capabilities, we aim to help address unmet medical needs such as cancer and other non-communicable diseases (NCDs) and rare diseases, which represent access-to-healthcare challenges common in developed countries. At the same time, through various collaborative partnerships, we aim to address unmet medical needs in developing countries such as malaria, tuberculosis, neglected tropical diseases (NTDs).

Availability

Pharmaceutical products only fulfill their purposes as medicine if they can be delivered to patients, and if these patients are able to use them properly. It is recognized that there are many patients with insufficient access to pharmaceuticals due to inadequate supply chains or counterfeit medicines in developing countries and issues with healthcare systems or other factors not only limited to developing countries but are found throughout many regions in the world. While considering the economic and market conditions in each country/region, we approach and work together with various organizations with the aim of improving the availability of pharmaceuticals.

Capacity Building

The various barriers impeding access to healthcare in developing countries include, inadequate healthcare systems and infrastructure, shortages of human capital capable of manufacturing pharmaceuticals and effectively manage quality control, and healthcare professionals. We are committed to fully leveraging our resources with the aim of implementing initiatives that generate the greatest possible impact.

Daiichi Sankyo Group

Nobuo Murakami

Head of Global Corporate Strategy

Issue Date: September 1st, 2018

Last Update: April 1st, 2026